Endpoints News
Facts
- Sectors
- Media, Biotech reporting
- Founded
- 2016
BrainChild Bio Raises $116M Series A on Sept. 8 to Fund Phase 2 B7-H3 CAR T Trial for DIPG
BrainChild Bio raised $116 million in a Series A on Sept. 8 to fund a registrational Phase 2 trial of BCB-276, a B7-H3 CAR T therapy delivered directly into cerebrospinal fluid for DIPG, and to advance a triple-antigen glioblastoma program. The Seattle Children’s spinout aims to bypass the blood-brain barrier with intrathecal delivery after promising early survival signals.
Gennev Founder Jill Angelo Steps Down After Acquisition; Aurion Biotech CEO Replaced Following Alcon Majority Stake; Temporal Adds New Leadership
Jill Angelo, founder and CEO of menopause startup Gennev, stepped down following its acquisition by Unified Women’s Healthcare, while Aurion Biotech replaced CEO Greg Kunst with Arnaud Lacoste after Alcon acquired a majority stake. Temporal also announced leadership additions with Jim Cyb as president and Sahir Azam as an independent board member.
Affini-T Therapeutics Closes Seattle Lab, Offering Some Employees Relocation to Boston
Affini-T Therapeutics, a cell therapy company specializing in T cell receptor cancer immunotherapy, is closing its Seattle lab, impacting 17 employees, some of whom may relocate to Boston. The company raised $175 million last year and was spun out of Fred Hutchinson Cancer Research Center.
Seattle-Area Longevity Biomedical to Go Public via SPAC in Q2 2023, Raising $30M with $236M Valuation
Longevity Biomedical, formed by merging Seattle-area startups Cerevast Medical, NovoKera, and Aegeria Soft Tissue, plans to go public via a SPAC merger expected to close in Q2 2023, raising at least $30 million. The combined company targets healthspan extension with treatments for stroke, blindness, and soft-tissue reconstruction, and is valued at $236.2 million.
Intrinsic Medicine Terminates $178.8M SPAC Deal With Phoenix Biotech Amid Market Downturn
Seattle biotech startup Intrinsic Medicine's planned $178.8 million SPAC merger with Phoenix Biotech Acquisition Corp. has been terminated due to market conditions. The company had previously withdrawn its traditional IPO filing and plans to advance clinical trials for its sugar-based therapeutic molecules.
Seattle Biotech Intrinsic Medicine to Go Public via SPAC Merger Raising $178.8M for Human Milk-Based Therapies
Seattle biotech startup Intrinsic Medicine, developing therapies based on human milk molecules, plans to go public via a SPAC merger with Phoenix Biotech Acquisition Corp to raise $178.8 million. The company aims to initiate a phase 2 trial for irritable bowel syndrome with top-line data expected in the first half of 2024.
David Baker Launches London Biotech Charm Therapeutics with $50M Series A to Advance Deep Learning Drug Discovery
David Baker, leader of the University of Washington Institute for Protein Design, co-founded London-based Charm Therapeutics, which uses deep learning to discover new small molecule therapeutics, and recently secured $50 million in Series A funding. The company's DragonFold platform predicts protein-small molecule interactions to aid drug discovery in cancer and other diseases.
